The Effect of a NSAID Drug on the Expression of Inflammatory Genes in Prostate Cancer Cells
Subject Areas :
Journal of Animal Biology
Fatemeh Moghbeli
1
,
Mohammad Morad Farajollahi
2
,
Abbas Mirshafiey
3
,
Monireh Mohsenzadegan
4
1 - Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
2 - Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
3 - Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
4 - Department of Medical laboratory science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
Received: 2020-12-24
Accepted : 2021-03-18
Published : 2021-11-22
Keywords:
prostate cancer,
Inflammatory,
NSAID Drug,
Inflammatory in Cancer,
Abstract :
Inflammation is a physiological process begining with tissue damage in the presence of various infectious agents, and men with symptoms of chronic inflammation in their noncancerous prostate tissue are about twice as likely as other men to develop advanced prostate cancer. Considering the importance of inflammatory factors in the invasion and metastasis of prostate cancer cells, we decided to evaluate the effect of the anti-inflammatory drug M2000 on two inflammatory genes involved in the invasion of cancer cells. PC3 cells were first cultured using RPMI medium with 10% FBS and 1% PenStrep. The cells were then treated with M2000 at concentrations of 25 and 50 μg/ml and after 24 hours the expression of il-8 and NF-κB were examined using real-time RT-PCR. NF-κB was assessed using real-time RT-PCR. In this study, NF-κB gene expression decreased in all treatments in RT-PCR. While the il-8 decreases in expression at a concentration of 50 μg/ml. The results of the present study showed that M2000 can reduce the expression of il-8 and NF-κB genes involved in tumorigenesis and invasion of prostate cancer cells, which could pave the way for future studies to better control prostate cancer.
References:
Albini A., Sporn MB. 2007. The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer, 7(2): 139-147.
Atretkhany K.-S., Drutskaya M., Nedospasov S., Grivennikov S., Kuprash D., 2016. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacology and Therapeutics, 168: 98-112.
Ben-Neriah Y., Karin M., 2011. Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunology, 12(8): 715.
Davis J.W., Mmeje C., 2016. Advances in Prostate Cancer Diagnosis: Triggers for Prostate Biopsy. Prostate Cancer: Leading-edge Diagnostic Procedures and Treatments, DOI: 10.5772/64402.
Fattahi M.J., Jamshidi A.R., Mahmoudi M., Vojdanian M., Yekaninejad M.S., Jafarnezhad-Ansariha F., Ahmadi H., Rehm B.H., Matsuo H., Cuzzocrea S. 2018. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. International immunopharmacology, 54: 112-117.
Gambara G., De Cesaris P., De Nunzio C., Ziparo E., Tubaro A., Filippini A., Riccioli A., 2013. Toll‐like receptors in prostate infection and cancer between bench and bedside. Journal of cellular and molecular medicine, 17(6): 713-722.
Hosseini S., Abdollahi M., Azizi G., Fattahi M. J., Rastkari N., Zavareh F. T., Aghazadeh Z., Mirshafiey A., 2017. Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. Journal of Basic and Clinical Physiology and Pharmacology, 28(3): 249-255.
Jelińska M., Skrajnowska D., Wrzosek M., Domanska K., Bielecki W., Zawistowska M., Korczak B. B., 2020. Inflammation factors and element supplementation in cancer. Journal of Trace Elements in Medicine and Biology, 59: 126450.
Karin M., Ben-Neriah Y., 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annual review of immunology, 18(1): 621-663.
Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S. L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K., 2000. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research, 60(5): 1306-1311.
Mirshafiey A., 2017. Pharmaceutical use of beta-D-mannuronic acid. EP067919.
Mirshafiey A., Cuzzocrea S., Rehm B., Matsuo H., 2005. M2000: a revolution in pharmacology. Medical science monitor, 11(8): PI53-PI63.
Moossavi M., Parsamanesh N., Bahrami A., Atkin S. L., Sahebkar A., 2018. Role of the NLRP3 inflammasome in cancer. Molecular cancer, 17(1): 158.
Pihan G.A., Wallace J., Zhou Y., Doxsey S.J. 2003. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Reserch, 63(6): 1398-1404.
Roozbehkia M., Mahmoudi M., Aletaha S., Rezaei N., Fattahi M. J., Jafarnezhad-Ansariha F., Barati A., Mirshafiey A., 2017. The potent suppressive effect of β-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB signaling pathway in ankylosing spondylitis patients. International immunopharmacology, 52: 191-196.
Schatten H. 2018. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies Cell & Molecular Biology of Prostate Cancer, pp. 1-14.
Sfanos K.S., Isaacs W.B., De Marzo A.M., 2013. Infections and inflammation in prostate cancer. Americn Journal of Clinical and Experimental Urology, 1(1): 3-11.
Turner M.D., Nedjai B., Hurst T., Pennington D.J. 2014. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1843(11): 2563-2582.
Vandercappellen J., Van Damme J., Struyf , 2008. The role of CXC chemokines and their receptors in cancer. Cancer Letters, 267(2): 226-244.
Wang N., Zhou R., Wang C., Guo X., Chen Z., Yang S., Li Y., 2012. T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case–control studies. Molecular Biology Reports, 39(3): 2831-2841.
_||_